Senate Skips Critical Measures In Step-By-Step 'Cures'
This article was originally published in Scrip
While many stakeholders in the biomedical community were happy just to see the Senate Health, Education, Labor and Pensions (HELP) Committee finally unveil a plan for moving forward with legislation aimed at making changes at the FDA and the National Institutes of Health (NIH) intended to accelerate medical innovation, there also was disappointment that the step-by-step strategy proposed by Sen. Lamar Alexander (R-TN), the panel's chairman, ignores several measures, like one focused on antibiotics development, that were included in a mega-bill adopted by the House last July – the 21st Century Cures Act.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.